Latest Research
Closed-Loop Insulin Systems Show Superior Outcomes Across All Age Groups in New Meta-Analysis
TechnologyA comprehensive review of 47 randomised trials found automated insulin delivery systems reduced time-in-range by an average of 14% compared to multiple daily injections, with benefits seen across Type 1 patients from age 2 to 75.
Semaglutide Reduces Kidney Disease Progression by 24% in Large Observational Study
MedicationThe FLOW trial confirmed that once-weekly semaglutide significantly reduced the risk of serious kidney disease events in people with Type 2 diabetes and chronic kidney disease, independent of its glucose-lowering effects.
Low-Carbohydrate Diet Achieves Type 2 Remission in 36% of Participants at 2 Years
DietA landmark trial published in The Lancet found that a structured low-carbohydrate dietary intervention, combined with weight loss support, achieved diabetes remission — defined as HbA1c below 48 mmol/mol without medication — in more than a third of participants.
CRISPR-Edited Beta Cells Survive Immune Attack in Early Human Trial
Gene TherapyResearchers report that gene-edited insulin-producing cells implanted in people with Type 1 diabetes showed signs of survival and function at 90 days without requiring immunosuppression — a significant hurdle in the field.
Non-Invasive Glucose Sensing: Where Are We in 2025?
TechnologyAn expert review assesses the current state of non-invasive blood glucose monitoring, including optical, sweat-based and electromagnetic approaches — and explains why a truly accurate needle-free device remains elusive despite significant investment.
Drug & Device Pipeline
Key diabetes treatments currently in development or recently approved.
| Drug / Device | Type | Indication | Stage | Notes |
|---|---|---|---|---|
| Tirzepatide (Mounjaro) | GIP/GLP-1 | Type 2 | Approved | Dual agonist — superior A1C reduction vs semaglutide |
| Semaglutide oral (Rybelsus) | GLP-1 | Type 2 | Approved | First oral GLP-1 receptor agonist |
| Insulin icodec | Weekly insulin | Type 1 & 2 | Approved (US) | Once-weekly basal insulin — major convenience gain |
| Zimhi (high-dose glucagon) | Rescue | Hypoglycaemia | Approved | Auto-injector for severe hypo rescue |
| Orforglipron | Oral GLP-1 | Type 2 / obesity | Phase 3 | Non-peptide oral GLP-1 — potentially cheaper to manufacture |
| Ultra-rapid aspart (Faster Aspart) | Mealtime insulin | Type 1 & 2 | Phase 3 | Faster onset for tighter post-meal control |
| Beta cell replacement therapy | Cell therapy | Type 1 | Phase 2 | Stem-cell derived beta cells — multiple trials ongoing |
About this table
Updated periodically based on published trial results and TGA/FDA announcements. For treatment decisions, always consult your endocrinologist or GP.